I think your analysis is incomplete. NVO's revenues and profitability have consistently grown year-over-year (including this year). And, that is despi

I think your analysis is incomplete. NVO's revenues and profitability have consistently grown year-over-year (including this year). And, that is despite President Trump’s threat to put 100% tariffs on them if they didn't lower their prices (substantially) and they did. But they have still grown their revenues in the trailing 12 months by nearly $2 billion dollars (and their gross profits by more than $1.2 billion) because their sales of their new weight loss pills have sold exponentially (i.e. incredibly well). Moreover, Trump won't be President forever. In fact, the Democrats are likely to retake Congress and the U.S. Senate in this fall's midterms, and the Whitehouse in 2028. And they will likely undo most, if not all, of what Trump has done, which should benefit companies like Novo Nordisk that import pharmaceuticals into the United States. Plus, the Supreme Court has also recently overturned Trump's tariffs, and (check me on this), ordered them to be returned to the companies affected. In addition, in the Novo suit against Lilly for false advertising. I saw the ads. Lilly claimed studies showed their weight loss medication (as I recall it) outperformed NVO's, but in the not so small print, they (Lilly) stated the results of their study might not be reliable and the weight loss might be attributable to other things such as diet and exercise. (That's what I recall from seeing their ads.) If Novo is successful in their lawsuit against Lilly, and I think they will be, Lilly could be ordered to pay Novo billions of dollars in damages. So, stay tuned.

PS - the other beautiful thing is Novo Nordisk (aka ticker symbol NVO - the maker of the best selling, most effective weight loss drugs Wegovy and Ozempic) (you've seen all of those celebrities and politicians on TV with those suddenly skinny faces - they don't call it "Ozempic face" for nothing) is currently paying an annual dividend of $1.80 (at today's price) which amounts to an annual yield of 3.9%. (That is nearly 7 times the annual dividend of competitor Ely Lilly (LLY), whose annual dividend is a paltry 0.57%.) Moreover, Lilly's current P/E is an enormous 41.06, whereas NVO's P/E at today's price is a very modest or meager 11.38, which makes them a great bargain in my book. In addition, Lilly's gross profit to gross revenue ratio is 83% (i.e. of its gross revenues, 83% is profit), compared to NVO's gross profit to gross revenue ratio is nearly identical at 82%. So that begs the question - Why is Lilly trading at 41 times its earnings but Novo Nordisk (NVO) is only trading at 11 times earnings? (As Novo's CEO recently said at their 2nd quarter meeting, eventually the market will figure it out and catch up.)